Submitted by International Federation of Pharmaceutical Manufacturers & Associations
Fight the Fakes is proud to announce that the International Alliance of Patients’ Organizations (IAPO) is joining as the campaign’s 36th partner. By signing up to join Fight the Fakes, IAPO will support awareness raising about fake medicines generally, but also throughout more than 265 member patient organizations around the world. IAPO represents patients across all disease areas and their engagement in the Fight the Fakes campaign will be invaluable, complementing the existing campaign partnership coalition reaching not only the general public but also thousands of nurses, pharmacists, researchers, NGOs and foundations, academic institutions and their students, pharmaceutical wholesalers, and the research-based and generics pharmaceutical industry.
By joining, IAPO will amplify Fight the Fakes’ voice through its vast global network of patient groups in over 70 countries. “We are excited to join Fight the Fakes and speak up about the threats that fake medicines pose to patients all around the world. The November 2017 WHO reports on substandard and falsified medicines have shown the global prevalence of fake medicines and we are looking forward to supporting awareness raising efforts and lend our voice to Fight the Fakes growing global movement” said Jolanta BiliÅ„ska, Chair of the International Alliance of Patients’ Organizations. “Patient exposure to falsified medication is a chronic public health issue that results in delayed care, disease progression, increased mortality and antimicrobial resistance. It also contributes to distrust of government, health care systems, and health care professionals. In short, it is a crime against patients. Every patient has the right to receive medicines that are safe, effective, and legitimate”.
Jolanta BiliÅ„ska adds: “Awareness raising and global patient empowerment are at the heart of what we do. Addressing falsified medicines requires general education and knowledge of the dangers. Everyone should have the tools and sufficient education on what they can do if they suspect a medicine to be falsified and how to challenge policymakers to prioritize and act on this important issue”.
Since its launch five years ago, “Fight the Fakes has grown to include among its partners virtually all key players involved in medicines and vaccines from the research labs to the pharmacies,” explains Chris Goetz from the IFPW Foundation, currently running the Fight the Fakes Secretariat, “with IAPO joining, we can say we reach all the people involved from lab to bathroom cabinet.”
About Fight the Fakes
Fight the Fakes is a campaign that aims to raise awareness about the dangers of fake medicines. The campaign gives a voice to those who have been personally impacted and shares the stories of those working to put a stop to this threat to public health. It seeks to build a global movement of organizations and individuals who will shine light on the negative impact that fake medicines have on people around the globe and to reduce the negative consequences on individuals worldwide. Fight the Fakes campaign is the first campaign to address the issue of responsibility from the beginning to the end of the pharmaceutical supply chain, by involving and coordinating stakeholders from a wide range of backgrounds.
The International Alliance of Patients’ Organizations (IAPO) is a unique global alliance of member organizations representing patients of all nations across all disease areas who work to get the patient’s voice heard by everyone involved in healthcare. We nurture relationships with members, partners and all those involved in healthcare, and build dialogue with decision-makers around the world to promote patient-centred healthcare. We form clear positions on relevant healthcare policies and processes and then advocate for change with a strong patients' voice at international, regional and national level. Our vision is to see patients placed at the centre of healthcare. Our mission is to help build patient-centred healthcare worldwide.
About falsified medicines
The WHO defines falsified medicines as medicines that deliberately/fraudulently misrepresent their identity, composition or source. Nearly any type of pharmaceutical product can be and has been falsified: whether “lifestyle” medicines, including erectile dysfunction and weight loss medicines, or lifesaving medicines including those used to treat malaria, tuberculosis, HIV/AIDS, cancer, heart disease, diabetes and other life-threatening conditions. Manufacturers of fake medicines do not discriminate –fake medicines can be both long established and recently marketed medicines, both branded and generic, and both domestically manufactured and imported.
Rachel Githinji, IAPO Communications Officer: email@example.com
The International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) represents research-based pharmaceutical companies and associations across the globe. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community find solutions that improve global health.
Research-based pharmaceutical companies make a unique contribution to global health as innovators of life-saving and life-changing medicines and vaccines, which improved millions of lives around the world. Both IFPMA and its companies are involved in hundreds of partnerships, including the new Access Accelerated initiative, a partnership of over 20 biopharmaceutical companies developing innovative and sustainable solutions to improve access to non-communicable disease (NCDs) treatment and care in low- and middle income countries. Access Accelerated also partners with the World Bank and the Union of International Cancer Control to help address the full spectrum of access barriers to NCD medicines. These partnerships involve the discovery of treatments that threaten health security or unduly put a burden on low income countries, as well as support Universal Health Coverage (UHC) by expanding access to medicines and vaccines and strengthening health systems and in doing so, contribute to the Sustainable Development Goals (SDG 3 and SDG 17).
IFPMA hosts the Secretariat of the AMR Industry Alliance, a coalition of over 100 biotechnology, diagnostic, generics and research-based biopharmaceutical companies and trade associations that was formed to drive and measure industry progress to curb antimicrobial resistance. The AMR Industry Alliance ensures that signatories collectively deliver on the specific commitments made in the Industry Declaration on AMR and the Roadmap and measures progress made in the fight against antimicrobial resistance.